

Table S3. Association of chronic kidney disease (CKD) characteristics with changes in echocardiographic measures from CKD to end-stage-renal-disease (ESRD) for participants who initiated dialysis (n=417)^{1, 2}

| Variable | Change from CKD to ESRD | | | | | | | | | |
|--|-------------------------|--------------|------------------|---------------|--------------------|--------------------------------------|---------------|---------------------------------------|--------------|--|
| | LVMI | | LVEF | | Diastolic function | Left ventricular end-systolic volume | | Left ventricular end-diastolic volume | | |
| | Beta±SE | p-value | Beta±SE | p-value | OR (95% CI) | Beta±SE | p-value | Beta±SE | p-value | |
| Age, year | -0.09±0.05 | 0.09 | 0.05±0.04 | 0.2 | 0.99 (0.96, 1.01) | -0.09±0.04 | 0.01 | -0.14±0.04 | 0.001 | |
| Female (ref=Male) | -1.31±1.20 | 0.3 | 2.01±0.86 | 0.02 | 1.34 (0.76, 2.36) | -1.96±0.83 | 0.02 | -2.85±1.00 | 0.005 | |
| Race (ref=Non-Hispanic white) | | | | | | | | | | |
| Non-Hispanic black | -2.09±1.61 | 0.2 | 1.06±1.10 | 0.3 | 0.63 (0.31, 1.26) | -1.88±1.08 | 0.08 | -2.69±1.31 | 0.04 | |
| Hispanic | -2.08±1.93 | 0.3 | 1.92±1.34 | 0.2 | 0.61 (0.27, 1.41) | -1.17±1.29 | 0.4 | -1.02±1.56 | 0.5 | |
| Other | -4.66±3.27 | 0.2 | 2.16±2.35 | 0.4 | 0.60 (0.11, 3.39) | -2.82±2.37 | 0.2 | -3.59±2.79 | 0.2 | |
| Systolic blood pressure at CKD, mmHg | -0.01±0.03 | 0.7 | 0.04±0.02 | 0.02 | 0.98 (0.97, 1.00) | -0.05±0.02 | 0.004 | -0.05±0.02 | 0.03 | |
| Hemoglobin level at CKD, g/dl | 0.69±0.37 | 0.06 | 0.15±0.25 | 0.6 | 1.04 (0.88, 1.23) | 0.50±0.25 | 0.04 | 0.88±0.30 | 0.004 | |
| Cardiovascular disease at CKD | 0.85±1.21 | 0.5 | -0.83±0.86 | 0.3 | 0.97 (0.55, 1.70) | -0.21±0.83 | 0.8 | -0.33±1.00 | 0.7 | |
| Diabetes at CKD | 1.64±1.28 | 0.2 | -0.70±0.92 | 0.4 | 0.71 (0.39, 1.29) | 0.51±0.89 | 0.6 | 0.74±1.07 | 0.5 | |
| ACE inhibitors or ARBs use at CKD | 1.20±1.26 | 0.3 | -0.83±0.90 | 0.4 | 0.95 (0.52, 1.73) | 0.39±0.87 | 0.7 | 0.43±1.06 | 0.7 | |
| Beta blockers use at CKD | 0.71±1.24 | 0.6 | -1.16±0.87 | 0.2 | 1.13 (0.63, 2.01) | -0.24±0.86 | 0.8 | -0.45±1.04 | 0.7 | |
| Calcium channel blockers use at CKD | -1.53±1.23 | 0.2 | 2.93±0.87 | 0.0008 | 1.00 (0.56, 1.79) | -2.89±0.84 | 0.0007 | -2.88±1.03 | 0.005 | |
| Diuretics use at CKD | 1.63±1.37 | 0.2 | -0.10±0.98 | 0.9 | 0.75 (0.39, 1.44) | -1.34±0.95 | 0.2 | -1.47±1.16 | 0.2 | |
| Number of anti-hypertensive med classes at CKD | 0.16±0.41 | 0.7 | -0.02±0.28 | 0.9 | 0.88 (0.73, 1.06) | -0.56±0.27 | 0.04 | -0.70±0.33 | 0.04 | |
| eGFR slope | -1.02±0.36 | 0.005 | 0.32±0.28 | 0.3 | 1.01 (0.84, 1.21) | -0.12±0.26 | 0.6 | -0.17±0.31 | 0.6 | |
| Peritoneal dialysis (ref=Hemodialysis) | -2.96±1.67 | 0.08 | 3.84±1.19 | 0.001 | 0.57 (0.24, 1.33) | -3.45±1.14 | 0.003 | -3.79±1.37 | 0.006 | |
| Changes in ACE inhibitors or ARBs from CKD to ESRD (ref=Unchanged) | | | | | | | | | | |

Change from CKD to ESRD

| Variable | LVMI | | LVEF | | Diastolic function | Left ventricular end-systolic volume | | Left ventricular end-diastolic volume | | |
|--|-------------------|-------------|------------|---------|--------------------|--------------------------------------|-------------|---------------------------------------|--------------|--|
| | Beta±SE | p-value | Beta±SE | p-value | OR (95% CI) | Beta±SE | p-value | Beta±SE | p-value | |
| Started | 0.30±1.89 | 0.9 | 1.61±1.43 | 0.3 | 1.41 (0.57, 3.47) | -1.48±1.41 | 0.3 | -1.17±1.72 | 0.5 | |
| Stopped | 1.42±1.42 | 0.3 | 0.85±0.99 | 0.4 | 0.95 (0.51, 1.79) | -0.19±0.95 | 0.8 | 0.38±1.15 | 0.7 | |
| Changes in beta blockers from CKD to ESRD (ref=Unchanged) | | | | | | | | | | |
| Started | 0.90±1.52 | 0.6 | 0.42±1.07 | 0.7 | 0.96 (0.47, 1.96) | 0.36±1.03 | 0.7 | 0.51±1.25 | 0.7 | |
| Stopped | 2.62±1.89 | 0.2 | -2.47±1.37 | 0.07 | 0.96 (0.36, 2.56) | 0.79±1.35 | 0.6 | 0.20±1.65 | 0.9 | |
| Changes in calcium channel blockers from CKD to ESRD (ref=Unchanged) | | | | | | | | | | |
| Started | -0.01±1.68 | 1.0 | -1.22±1.21 | 0.3 | 0.61 (0.26, 1.44) | -0.19±1.16 | 0.9 | -1.15±1.41 | 0.4 | |
| Stopped | -3.74±1.53 | 0.01 | 0.72±1.08 | 0.5 | 0.61 (0.29, 1.27) | -2.58±1.04 | 0.01 | -3.44±1.25 | 0.006 | |
| Changes in diuretics from CKD to ESRD (ref=Unchanged) | | | | | | | | | | |
| Started | -2.69±2.33 | 0.2 | -0.55±1.71 | 0.7 | 1.31 (0.42, 4.08) | 0.27±1.61 | 0.9 | -1.12±1.96 | 0.6 | |
| Stopped | -1.22±1.27 | 0.3 | -0.35±0.91 | 0.7 | 1.25 (0.70, 2.25) | -0.36±0.87 | 0.7 | -0.70±1.06 | 0.5 | |

Bolded values have p<0.05

¹Linear regression is used for continuous echocardiographic measures; ordinal logistic regression is used for categorical echocardiographic measures.

²All models are adjusted for its echocardiographic measures at CKD.

CKD=chronic kidney disease; ESRD=end-stage renal disease